EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease

Salman Al-Sabah, Irina Al-Khairi, Mohammad Jamal, Mohammad Qaddoumi, Fahad Alajmi, Jijin Kumar, Nermeen Abukhalaf, Preethi Cherian, Dhanya Madhu, Hossein Arefanian, Carol Dsouza, Nada Alam-Eldin und 6 weitere

Medical Principles and Practice · 24.07.2024 · 33 (5) · 478-490

DOI: 10.1159/000540534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Principles and Practice, online erschienen am 24.07.2024. Verfasst von Salman Al-Sabah und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, College of Medicine, Kuwait University, Kuwait City, Kuwait. Hauptthemen laut MEDLINE: Bariatric Surgery, Rats, Sprague-Dawley, Weight Loss, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Bariatric surgery is a well-established treatment for obesity and type 2 diabetes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as a promising therapy for type 2 diabetes. This study aimed to compare the effects of bariatric surgery, semaglutide (a GLP-1 receptor agonist), and tirzepatide in Sprague-Dawley rats fed a high-fat diet.

Methods

Rats were divided into surgery, semaglutide, and tirzepatide treatment groups, along with a control group (sham). Weight, oral glucose tolerance, and levels of metabolic markers were assessed, along with adipose and liver tissue analysis.

Results

Surgery led to a 15.5% weight reduction, while rats treated with semaglutide exhibited a 10.7% reduction. Tirzepatide treatment at various concentrations (10, 50, and 100 nmol/kg) resulted in weight reductions of 5.0%, 14.9%, and 17.7%, respectively, compared to the sham group. Metabolic analyte levels decreased in intervention groups compared to the sham group, indicating improved metabolic health and glucose tolerance. Adipose tissue weight and hepatic liver fat droplets decreased in the intervention groups.

Conclusion

Bariatric surgery and tirzepatide treatment significantly improved metabolic parameters in obese rats. Tirzepatide, particularly at higher concentrations, showed pronounced improvements compared to surgery and semaglutide. These findings suggest that high doses of tirzepatide could be explored as an alternative to bariatric surgery for the treatment of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryRats, Sprague-DawleyWeight LossNon-alcoholic Fatty Liver DiseaseGlucagon-Like PeptidesAnimalsRatsMaleObesityDiet, High-FatReceptors, Gastrointestinal HormoneGlucose Tolerance TestGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Stichwörter der Autor:innen

Bariatric surgeryMetabolic analytesObesity treatmentTirzepatideType 2 diabetes

Substanzen

Glucagon-Like PeptidesReceptors, Gastrointestinal HormoneGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsSemaglutidegastric inhibitory polypeptide receptor

Autor:innen und Institutionen

  • Department of Surgery, College of Medicine, Kuwait University, Kuwait City, Kuwait.
  • Department of Surgery, Jaber Al-Ahmed Hospital, Kuwait City, Kuwait.
  • Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman, Kuwait City, Kuwait.
  • Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Kuwait City, Kuwait.
  • Animal and Imaging Core Facilities, Dasman Diabetes Institute, Kuwait City, Kuwait.
  • Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait.

Zitieren

APA

Al-Sabah, S., Al-Khairi, I., Jamal, M., Qaddoumi, M., Alajmi, F., Kumar, J., Abukhalaf, N., Cherian, P., Madhu, D., Arefanian, H., Dsouza, C., Alam-Eldin, N., AlSabagh, A., Al Madhoun, A., Al-Sabah, S., Al-Mulla, F., Abu-Farha, M., & Abubaker, J. (2024). Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease. Medical Principles and Practice, 33(5), 478-490. https://doi.org/10.1159/000540534

Vancouver

Al-Sabah S, Al-Khairi I, Jamal M, Qaddoumi M, Alajmi F, Kumar J, et al. Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease. Medical Principles and Practice. 2024;33(5):478-490. doi:10.1159/000540534

BibTeX
@article{AlSabah2024,
  author = {Al-Sabah, Salman and Al-Khairi, Irina and Jamal, Mohammad and Qaddoumi, Mohammad and Alajmi, Fahad and Kumar, Jijin and Abukhalaf, Nermeen and Cherian, Preethi and Madhu, Dhanya and Arefanian, Hossein and Dsouza, Carol and Alam-Eldin, Nada and AlSabagh, Abdullah and Al Madhoun, Ashraf and Al-Sabah, Suleiman and Al-Mulla, Fahd and Abu-Farha, Mohamed and Abubaker, Jehad},
  title = {Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease},
  journal = {Medical Principles and Practice},
  year = {2024},
  volume = {33},
  number = {5},
  pages = {478--490},
  doi = {10.1159/000540534}
}
Kostenlos starten →